News Posts List
Low cholesterol may increase kidney cancer patients' risk of dying
06/12/2014
Patients with high cholesterol had a 43 percent lower risk of dying.
Phase 1 Cancer Trial for Altiratinib (DCC-2701) MET/TIE2/VEGFR/TRK Kinase Inhibitor for Solid Tumors
05/31/2014
Deciphera Pharmaceuticals a clinical stage biotechnology company focused on improved kinase inhibitor treatments for cancer today announced the initiation of a Phase 1 clinical trial of its MET/TIE2/VEGFR2/TRK inhibitor altiratinib (DCC-2701). The Phase 1 trial will evaluate the safety tolerability and initial efficacy of altiratinib in cancer patients with solid tumors. Altiratinib has been shown to exhibit high potency and selectivity for inhibiting MET TIE2 VEGFR2 and TRK kinases in preclinical studies. A companion diagnostic assay will also be co-developed during the course of clinical studies.
ASCO 2014 Renal Cell Carcinoma Abstracts
05/31/2014
Abstracts mentioning renal cell carcinoma (kidney cancer) from the 2014 ASCO Annual Meeting in Chicago.
Cell-Cycle Gene Test Shows Early Promise in Clear Cell RCC - See more at: http://www.onclive.com/conference-coverage/aua-2014/Cell-Cycle-Gene-Test-Shows-Early-Promise-in-Clear-Cell-RCC#sthash.DhoRovxs
05/21/2014
A cell-cycle gene array test demonstrated independent value for predicting metastatic progression after surgery for organ-confined renal cell carcinoma (RCC) of clear cell histology...
Intratumour heterogeneity in renal and lung cancer
05/21/2014
Prof Swanton discusses his presentation at the recent European International Kidney Cancer Symposium sponsored by US based Kidney Cancer Association
Results of our recent Affordable Care Act (Obamacare) survey
05/21/2014
Nearly half of respondents report losing access to doctors, hospitals, and treatments
Centrose receives National Cancer Institute grant
05/20/2014
Madison-based biotech firm Centrose received a six-month $224,734 grant...
An antimicrobial drug may help in treating advanced kidney cancer
05/07/2014
"The strategy of repurposing drugs that are currently being used for other indications is of significant interest to the medical community..."
Study Confirms Clinical Benefit for Interleukin-2
05/07/2014
Patients with metastatic renal cell carcinoma face a poor prognosis; currently, 30% of patients already have metastatic disease at the time of diagnosis, according to national data.
Surgical strategies available for renal cell carcinoma
05/07/2014
Prof Wood talks to ecancertv at the EIKCS conference about the different surgical strategies available for approaching renal cell carcinoma with inferior vena cava invasion and their outcomes post-surgery.
News Feed